PF-Atlas › Clinical Trials › NCT00070590

Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma

Bosentan · Phase 2

Registry ID
NCT00070590
Phase
Phase 2
Status
Completed
Drug / intervention
Bosentan
Sponsor
Actelion
Start
2003-07
Enrollment
132

About this trial

Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is available. The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients suffering from ILD associated with SSc.

View NCT00070590 on ClinicalTrials.gov →

Explore related

All Bosentan trialsAll IPF trials

Related trials

Bosentan — NCT00318175bosentan — NCT00625469bosentan — NCT01518595Bosentan — NCT00631475bosentan — NCT00071461Bosentan — NCT00637065
Medical disclaimer. This page summarizes public trial data for NCT00070590 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.